Clinical Trial Update: Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating regorafenib in combination with nivolumab for mismatch repair–refractory colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Stivarga (regorafenib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Colorectal Cancer, Metastatic Colorectal Cancer | Phase 1 | Status: COMPLETED